Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 1
2020 2
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Disease in the Systemic Vasculitides.
Soulaidopoulos S, Madenidou AV, Daoussis D, Melissaropoulos K, Mavrogeni S, Kitas G, Dimitroulas T. Soulaidopoulos S, et al. Among authors: madenidou av. Curr Vasc Pharmacol. 2020;18(5):463-472. doi: 10.2174/1570161118666200130093432. Curr Vasc Pharmacol. 2020. PMID: 32000652 Review.
Real-life experience of tocilizumab use in COVID-19 patients.
Madenidou AV, Bukhari M. Madenidou AV, et al. Rheumatology (Oxford). 2020 Aug 1;59(8):2163-2166. doi: 10.1093/rheumatology/keaa325. Rheumatology (Oxford). 2020. PMID: 32556278 Free PMC article. No abstract available.
Adalimumab or etanercept as first line biologic therapy in enthesitis related arthritis (ERA) - a drug-survival single centre study spanning 10 years.
Shipa MR, Heyer N, Mansoor R, Deakin CT, Madenidou AV, Bouraioui A, Fisher C, Leandro M, Ciurtin C, Sen D. Shipa MR, et al. Among authors: madenidou av. Semin Arthritis Rheum. 2022 Aug;55:152038. doi: 10.1016/j.semarthrit.2022.152038. Epub 2022 May 28. Semin Arthritis Rheum. 2022. PMID: 35660170 Free article.
Switching patients with inflammatory arthritis from Etanercept (Enbrel®) to the biosimilar drug, SB4 (Benepali®): A single-centre retrospective observational study in the UK and a review of the literature.
Madenidou AV, Jeffries A, Varughese S, Jones S, Sari-Kouzel H, Veevers H, Rao C. Madenidou AV, et al. Mediterr J Rheumatol. 2019 May 31;30(Suppl 1):69-75. doi: 10.31138/mjr.30.1.69. eCollection 2019 Jun. Mediterr J Rheumatol. 2019. PMID: 32524081 Free PMC article.